ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Renal"

  • Abstract Number: 2382 • ACR Convergence 2023

    Relapse of Patients with ANCA-associated Vasculitis Who Are on Dialysis

    Yeo-Jin Lee1, Hansun Song2, Wook Jang Seo3, Jinseok Kim4, Soo-Min Ahn1, Ji-Seon Oh5, Yong-Gil Kim2, Chang-Keun Lee1, Bin Yoo1 and Seokchan Hong1, 1Asan Medical Center, Seoul, South Korea, 2Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, 3Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea, 4Department of Rheumatology, Jeju National University Hospital, Jeju National University School of Medicine, Jeju-si, Jeju-do, South Korea, La Jolla, CA, South Korea, 5Department of Information Medicine, Big Data Research Center, Asan Medical Center, University of Ulsan College of Medicine, Ulsan, South Korea

    Background/Purpose: It is known that disease activity of ANCA-associated vasculitis (AAV) is decreased after dialysis. However, most studies have been conducted on Caucasians, and factors…
  • Abstract Number: 1394 • ACR Convergence 2023

    Comorbidities, Not Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs, May Be Associated with Chronic Kidney Disease in Patients with Ankylosing Spondylitis: A Nationwide Population-Based Study

    Bon San Koo1, Subin Hwang1, Ye-Jee Kim2, Soo Min Ahn2 and Wook Jang Seo3, 1Inje University Seoul Paik Hospital, Seoul, South Korea, 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, 3Department of Rheumatology, Veteran Health Service Medical Center, Seoul, South Korea

    Background/Purpose: Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed as first-line treatment for symptom relief and inflammation reduction in patients with ankylosing spondylitis (AS). However, long-term…
  • Abstract Number: 2493 • ACR Convergence 2023

    Renal Prognosis of Dialysis-dependent Patients at Baseline in ANCA-associated Vasculitis

    Maxime Vignac1, Dorian Nezam2, François Grolleau3, Pauline Morel4, Dimitri Titeca-Beauport5, Stanislas Faguer6, alexandre Karras7, Justine Solignac8, Noémie Jourde-Chiche9, Francois Maurier10, Hamza Sakhi1, Khalil El Karoui1, Rafik Mesbah11, Pierre Louis Carron12, Vincent Audard1, Didier Ducloux13, Romain Paule14, Jean-François Augusto15, Julien Aniort16, Aurélien Tiple16, Cédric Rafat1, Xavier Puéchal17, Pierre Gobert18, Catherine Hanrotel19, Stéphane Bally20, Nihal Martis21, Cécile-Audrey Durel22, Pascal Godmer23, Aurélie Hummel24, François Perrin25, Antoine Néel26, Claire De Moreuil27, Tiphaine Goulenok28, Dominique Guerrot29, Aurelie Foucher30, Alban DEROUX12, Loic Guillevin31, Alexis REGENT32, Raphaël Porcher3 and Benjamin Terrier33, 1APHP, Paris, France, 2CH du Havre, Havre, France, 3Université Paris Cité, Paris, France, 4AURA Paris Plaisance, Paris, France, 5CHU Amiens, Amiens, France, 6CHU Toulouse, Toulouse, France, 7HEGP - APHP, Paris, France, 8APHM, Marseille, France, 9AP-HM, Marseille, France, 10Hôpitaux privés de Metz, Vaux / Frankreich, France, 11Boulogne Hospital (CH), Boulogne, France, 12CHU de Grenoble, Grenoble, France, 13CHU de Besançon, Besançon, France, 14Hôpital Foch, Paris, France, 15CHU d'Angers, Angers, France, 16CHU de Clermont Ferrand, Clermont Ferrand, France, 17National Referral Center for Rare Systemic Autoimmune Diseases, Paris, France, 18Clinique Rhône Durance, Avignon, France, 19CHU Brest, Brest, France, 20CH Métropole Savoie, Chambery, France, 21CHU de Nice, Nice, France, 22CHU Lyon, Lyon, France, 23CH Bretagne Atlantique, Vannes, France, 24CHU Necker, Paris, France, 25CH Saint Nazaire, Saint Nazaire, France, 26CHU de Nantes, Nantes, France, 27CHU de Brest, Brest, France, 28Assistance Publique Hopitaux de Paris, Paris, France, 29CHU Rouen, Rouen, France, 30CHU de la Réunion, Saint pierre, France, 31University Paris Descartes, Paris, France, 32CHU Cochin, Université Paris Cité, Paris, France, 33Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France

    Background/Purpose: Renal involvement in ANCA-associated vasculitides (AAV) is an organ- and life-threatening manifestation and therefore an important prognostic factor. However, the identification of predictive factors…
  • Abstract Number: 1480 • ACR Convergence 2023

    Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region

    Jamal Al-Saleh1, Faisal Elbadawi1, Rajaie Namas2, Samar Al-Emadi3, Khalid A. Alnaqbi4, Humaid A. Al-Wahshi5, Amjad Alkadi6, Suad Hannawi7, Mohamed Hamouda8, Averyan Vasylyev8, Arwa Al-Shujairi8, Reem Al-Jayyousi9 and Munther Khamashta8, 1Dubai Hospital, Department of Rheumatology, Dubai, United Arab Emirates, 2Cleveland Clinic Abu Dhabi, Department of Rheumatology, Abu Dhabi, United Arab Emirates, 3Hamad Medical Corporation, Department of Rheumatology, Doha, Qatar, 4Tawam Hospital, Department of Rheumatology, Al Ain, United Arab Emirates, 5The Royal Hospital, Department of Rheumatology, Muscat, Oman, 6Ministry of Health, Kuwait, Kuwait, 7Kuwait Hospital, Department of Rheumatology, Dubai, United Arab Emirates, 8GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, 9Mohamed Bin Rashid University of Medicine and Health Sciences, College of Medicine, Dubai, United Arab Emirates, and Mediclinic Parkview, Dubai, United Arab Emirates

    Background/Purpose: Data from limited studies of LN in the Gulf region suggest that LN manifests more severely in this region than in Caucasian populations, yet…
  • Abstract Number: 0655 • ACR Convergence 2022

    Proteomic Analysis of Histological Lesions Lupus Nephritis Identifies an Inflammatory Signature of Fibrous Crescents

    Alessandra Ida Celia1, Jeffery Hodgin2, Avi Rosenberg3, Laurence S Magder4, Jill Buyon5, Betty Diamond6, Judith James7, William Apruzzese8, Paride Fenaroli9, Derek Fine1, Jose Monroy-Trujillo1, Mohamed G. Atta1, Peter izmirly10, Michael Belmont5, Anne Davidson6, Daniel W. Goldman11, the Accelerating Medicines Partnership (AMP) RA/SLE12, Michelle Petri11 and Andrea Fava1, 1Johns Hopkins University, Baltimore, MD, 2University of Michigan, Ann Arbor, MI, 3Johns Hopkins University, Ballwin, MO, 4University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD, 5NYU Grossman School of Medicine, New York, NY, 6Feinstein Institutes for Medical Research, Manhasset, NY, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Brigham and Women's Hospital, Boston, MA, 9Università degli Studi di Parma, Parma, Emilia-Romagna, Italy, 10NYU Long Island School of Medicine, New York, NY, 11Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 12Multiple Insitutions

    Background/Purpose: We employed urine proteomics to define the molecular signatures associated with the histological features quantified by the NIH activity and chronicity indices. Methods: Glomerular…
  • Abstract Number: 0929 • ACR Convergence 2022

    Severe Low-Dose Methotrexate Toxicity in Elderly Patients with Inflammatory Rheumatic Diseases

    Cara Kumar1, Kristine Herrmann1 and Martin Aringer2, 1Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, 2University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany

    Background/Purpose: While mostly remarkably safe, low dose methotrexate (MTX) occasionally causes life-threatening events. We analyzed all patients with rheumatic diseases and severe MTX toxicity between…
  • Abstract Number: 1055 • ACR Convergence 2022

    Associations of Potential Risk Factors with Severe Outcomes in Scleroderma Renal Crisis: Results from a Single Center Study

    Alex Luta1, Saloni Godbole1 and Virginia Steen2, 1Medstar Georgetown University Hospital, Washington, DC, 2Georgetown University School of Medicine, Washington, DC

    Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe and life-threatening complication of Systemic Sclerosis (SSc). Given the rare nature of SSc, it is challenging to…
  • Abstract Number: 1069 • ACR Convergence 2022

    Renal Involvement Other Than Renal Crisis in Systemic Sclerosis: A Retrospective Monocentric Cohort Study

    Gaelle Becel1, Bertrand Dunogue1, Benjamin Chaigne1, Benjamin Thoreau2, Alexis Regent1, Alexandre Karras3, Benjamin Terrier1 and Luc Mouthon1, 1National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 2AP-HP, Université Paris Cité, INSERM U1016, CNR UMR 8104, Paris, France, 3HEGP, Paris, France

    Background/Purpose: Scleroderma renal crisis has extensively been described over the past decades because of its severity. The use of angiotensin-converting enzyme inhibitors has clearly improved…
  • Abstract Number: 1073 • ACR Convergence 2022

    Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan

    Soko Kawashima1, Mitsumasa Kishimoto2, Yoshinori Komagata3 and Shinya kaname4, 1Kyorin University, Mitaka Tokyo, Japan, 2Kyorin University School of Medicine, Yokohama, Japan, 3Kyorin University School of Medicine, Tokyo, Japan, 4Kyorin University, Tokyo, Japan

    Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
  • Abstract Number: 1083 • ACR Convergence 2022

    Treatment of ANCA-associated Vasculitis with Extreme Impairment of Renal Function: A Case-Control Study Comparing an Intensive B Cell Depletion Regimen with the Standard of Care Using Oral Cyclophosphamide

    Dario Roccatello1, Savino Sciascia2, Stefano Murgia1, Giacomo Quattrocchio1, Michela Ferro1, Emanuele De Simone1, Carla Naretto1, Antonella Barreca1, Daniela Rossi1, Vittorio Modena1 and Roberta Fenoglio1, 1University of Turin, Turin, Italy, 2University of Turin, Torino, Italy

    Background/Purpose: Rituximab (RTX), an anti-CD20 monoclonal antibody, has shown to be an effective induction treatment for small-vessel vasculitis associated with antineutrophil cytoplasm antibodies (AAV) in…
  • Abstract Number: 1089 • ACR Convergence 2022

    Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

    Yeo jin lee1, Soo Min Ahn2, Ji Seon Oh3, Yong Gil Kim2, Chang Keun Lee2, Bin Yoo2 and Seokchan Hong2, 1Asan medical center, Seoul, Republic of Korea, 2Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, 3Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea

    Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease that can involve various organs systematically. Kidney involvement, one of the major manifestations of AAV,…
  • Abstract Number: 1360 • ACR Convergence 2022

    Clinical Characteristics and Outcomes of North American Youth with Lupus Nephritis Requiring Dialysis Treated with Cyclophosphamide

    Christine Wang1, Rebecca Sadun2, Wenru Zhou3, Kristen Miller3, Claire Palmer3, Stacy P Ardoin4, Christine Bacha5, Emily Hause6, Joyce Hui-Yuen7, Nicole Ling8, Maria Pereira9, Meredith Riebschleger10, Kelly Rouster-Stevens11, Aliese Sarkissian12, Julia Shalen13, William Soulsby14, Marinka Twilt15, Eveline Wu16, Laura Lewandowski17, Scott Wenderfer18 and Jennifer Cooper19, 1Children's Hospital of Colorado/University of Colorado, Denver, CO, 2Duke University, Durham, NC, 3University of Colorado School of Medicine, Aurora, CO, 4Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, 5Nationwide Children's Hospital, Columbus, OH, 6University of Minnesota, Minneapolis, MN, 7Cohen Children’s Medical Center, Hofstra-Northwell School of Medicine, Feinstein Institutes for Medical Research, Queens, NY, 8UCSF, San Francisco, CA, 9Baylor College of Medicine, Houston, TX, 10University of Michigan, Ann Arbor, MI, 11Emory University/Children's Healthcare of Atlanta, Atlanta, GA, 12University of North Carolina at Chapel Hill, Chapel Hill, NC, 13Johns Hopkins University, Baltimore, MD, 14University of California, San Francisco, San Francisco, CA, 15Alberta Children's Hospital, Calgary, AB, Canada, 16University of North Carolina, Chapel Hill, NC, 17NIAMS, NIH, Bethesda, MD, 18British Columbia Children's Hospital, Vancouver, BC, Canada, 19University of Colorado/Children's Hospital Colorado, Denver, CO

    Background/Purpose: Few studies have evaluated the clinical characteristics and outcomes of youth with lupus nephritis (LN) treated with cyclophosphamide (CYC) who initially required kidney replacement…
  • Abstract Number: 1483 • ACR Convergence 2022

    Etiology of Elevated Serum Creatinine in Patients with Systemic Lupus Erythematosus at Presentation and Association of Crescents in Renal Biopsy with Rapidly Progressive Renal Failure in a Lupus Cohort

    Rajat Kharbanda, Able Lawrence and Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

    Background/Purpose: Systemic lupus erythematosus (SLE) commonly involve kidney, with increase in creatinine due to lupus related or unrelated cause. Renal biopsy remains gold standard in…
  • Abstract Number: 1530 • ACR Convergence 2022

    Scleroderma Renal Crisis: Time to Initiation of Therapy Does Not Affect Mortality

    Aditi Patel1, Chao Zhang1 and Soumya Chatterjee2, 1Cleveland Clinic, Cleveland, OH, 2Cleveland Clinic, Richmond Heights, OH

    Background/Purpose: Scleroderma renal crisis (SRC) is a rare complication in patients with systemic sclerosis (SSc), characterized by accelerated hypertension and acute kidney injury. ACE inhibitors…
  • Abstract Number: 1636 • ACR Convergence 2022

    Long-term Renal Survival of Patients with LN by Renal Response Status in the Toronto Lupus Cohort

    Murray Urowitz1, Mary E. Georgiou2, Jiandong Su3, Anne MacKinnon3, Yulia Green4, Kerry Gairy2, Roger A Levy5 and Patricia C. Juliao6, 1University of Toronto, University Health Network, Schroeder Arthritis Institute, Toronto, ON, Canada, 2GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, 3University of Toronto Lupus Program, Schroeder Arthritis Institute, University Health Network, Division of Rheumatology, Toronto, ON, Canada, 4GlaxoSmithKline, Clinical Development, Brentford, United Kingdom, 5GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 6GlaxoSmithKline, Value Evidence and Outcomes, Collegeville, PA

    Background/Purpose: Approximately 40% of adult patients with SLE develop LN, which can lead to end-stage kidney disease (ESKD).1 Renal response is used in clinical trials…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology